<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/984B85E1-691A-4F72-B264-EA8C989632D3"><gtr:id>984B85E1-691A-4F72-B264-EA8C989632D3</gtr:id><gtr:name>Aptuit</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3ABB364D-B419-4E7D-9025-E67A73EC23F9"><gtr:id>3ABB364D-B419-4E7D-9025-E67A73EC23F9</gtr:id><gtr:name>Crucell</gtr:name><gtr:address><gtr:line1>Archimedesweg 4-6</gtr:line1><gtr:postCode>2333 CN</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/075641B7-F61C-49EC-8B70-E082B2D3B276"><gtr:id>075641B7-F61C-49EC-8B70-E082B2D3B276</gtr:id><gtr:name>Boots Contract Manufacturing (BCM)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Cancer Sciences</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/984B85E1-691A-4F72-B264-EA8C989632D3"><gtr:id>984B85E1-691A-4F72-B264-EA8C989632D3</gtr:id><gtr:name>Aptuit</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3ABB364D-B419-4E7D-9025-E67A73EC23F9"><gtr:id>3ABB364D-B419-4E7D-9025-E67A73EC23F9</gtr:id><gtr:name>Crucell</gtr:name><gtr:address><gtr:line1>Archimedesweg 4-6</gtr:line1><gtr:postCode>2333 CN</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/075641B7-F61C-49EC-8B70-E082B2D3B276"><gtr:id>075641B7-F61C-49EC-8B70-E082B2D3B276</gtr:id><gtr:name>Boots Contract Manufacturing (BCM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6EF1F700-9916-4D31-871E-3FFCCDD02955"><gtr:id>6EF1F700-9916-4D31-871E-3FFCCDD02955</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:surname>Lee</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/13A40F44-539E-4236-B36E-8AC64800F174"><gtr:id>13A40F44-539E-4236-B36E-8AC64800F174</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>James</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1D780C60-3496-4DAE-9EE4-21DB1B3823F1"><gtr:id>1D780C60-3496-4DAE-9EE4-21DB1B3823F1</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Francis</gtr:otherNames><gtr:surname>Searle</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8590F78C-DCAA-45D7-B9CB-D7652DCA0C0B"><gtr:id>8590F78C-DCAA-45D7-B9CB-D7652DCA0C0B</gtr:id><gtr:firstName>Vivien</gtr:firstName><gtr:surname>Mautner</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F9DD0CFB-32DB-42A7-A713-6C63F388B211"><gtr:id>F9DD0CFB-32DB-42A7-A713-6C63F388B211</gtr:id><gtr:firstName>Emilio</gtr:firstName><gtr:surname>Porfiri</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F394EA3E-4431-4AB4-A300-D3CA4F41857C"><gtr:id>F394EA3E-4431-4AB4-A300-D3CA4F41857C</gtr:id><gtr:firstName>Lawrence</gtr:firstName><gtr:otherNames>Sterling</gtr:otherNames><gtr:surname>Young</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0502050"><gtr:id>B00BBA16-3BAE-4536-B59D-72AA04217775</gtr:id><gtr:title>A study of Ad-NTR-GMCSF, given via brachytherapy, followed by CB1954 in patients with locally relapsed prostate cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0502050</gtr:grantReference><gtr:abstractText>Cancer of the prostate is the most common male tumour and approximately 10,000 men die of this disease every year in the UK. In most patients with tumours confined to the prostate, the cancer can be successfully eradicated using surgery or radiotherapy, nevertheless in about 20% of these patients the tumour relapses, initially within the prostate area but then spreads to other organs such as bone, liver, and lymph nodes. There is no effective treatment for relapsed prostate cancer, drugs that induce a decrease of male hormones can provide a temporary benefit but after one or two years of treatment the cancer becomes insensitive to these drugs. We are developing novel gene therapy treatments for prostate tumours which have relapsed within the prostate. In our current clinical trial we use a genetically modified virus to introduce in the cancer cells a ?suicide? gene which is able to convert an inactive compound (?prodrug?) in a powerful anti cancer drug. The modified virus is injected directly in the relapsed prostate tumour then the ?prodrug? is administered intravenously to the patient. When the ?prodrug? reaches the prostate it is rapidly converted by the suicide gene in an anticancer drug and kills the cancer cells which have been infected with the modified virus. This treatment strategy was safe and showed anti tumour efficacy. Building on these observations we are now planning a new clinical trial using an improved virus which will carry the same suicide gene in combination with a gene able to induce a strong immune response against the cancer cells. In addition, we will use a modified virus injection protocol in order to achieve a uniform distribution of the virus within the whole prostate and to improve the anti-tumour efficacy of our system.</gtr:abstractText><gtr:technicalSummary>We are developing Virus Directed Enzyme Prodrug Therapy (VDEPT) for the treatment of locally relapsed prostate cancer. Our current clinical trial has shown that the delivery of the Nitroreductase (NTR) gene to the cancer tissue using a replication defective adenovirus (CTL102), followed by the prodrug CB1954 is able to induce NTR expression and PSA responses as well as PSA stabilisations. Although the tolerability and the safety profile of CTL102/CB1954 was good, the tumour responses were short lived and viable cancer cells were found in all post treatment biopsies. It is likely that an insufficient distribution of CTL102 within the prostate and the suboptimal activity of CTL102/CB1954 were responsible for the low efficacy of our system. We are now proposing a new Phase I/II clinical trial incorporating two significant improvements relative to the current study.
(1) We plan to increase the activity of the CTL102/CB1954 system using an improved version of CTL102 expressing the gene for the GM-CSF as well as NTR (Ad-NTR-GMCSF). GM-CSF is a key regulator of the immune system which is thought to augment the antitumour response of the host by stimulating the recruitment and activity of dendritic cells. Preclinical observations have shown that GM-CSF is able to enhance the VDEPT induced immune bystander effect. Consistent with these data we have demonstrated that in mouse models the efficacy of NTR/CB1954 was greatly increased when using a vector co-expressing mGM-CSF and NTR compared to either modality used alone. 
(2) In our current trial CTL102 is given via ultrasound-guided trans-rectal injection. Although vector delivery via trans-rectal injection is safe and widely used in prostate cancer gene therapy, it is unlikely that this route of administration is able to cover the entire prostate tissue. We plan to improve the distribution of the virus within the prostate using a brachytherapy-type delivery of the viral vector. This type of administration ensures a more homogenous distribution of the virus within the whole prostate and is expected to result in a higher anti-tumour efficacy. 
Five groups of 3 patients each will be treated with increasing doses of Ad-NTR-GMCSF followed 48 h later by intravenous CB1954. Safety and feasibility as well as virus pharmacokinetic constitute the primary objectives of the study. Secondary objectives include the assessment of tumour responses, the study of histology in post treatment biopsies and the study of tumour-specific immune responses stimulated by the gene therapy.</gtr:technicalSummary><gtr:fund><gtr:end>2015-07-18</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-03-19</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>584114</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Boots Contract Manufacturing (BCM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>BCM Specials</gtr:department><gtr:description>CB1954 drug product manufacture</gtr:description><gtr:id>5794FD6B-AD94-412D-8056-6D0E9EC3AEE0</gtr:id><gtr:impact>CB1954 drug substance awaiting regulatory approvals, before final release to trial</gtr:impact><gtr:outcomeId>bGP55eM1q39-1</gtr:outcomeId><gtr:partnerContribution>Performed the cGMP formulation and fill, and GLP analytical assays of the CB1954 drug product</gtr:partnerContribution><gtr:piContribution>Contracted BCM Specials for the work, discussed appropriate methods, specifications, and analytical results</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aptuit</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Aptuit (Oxford)</gtr:department><gtr:description>Purification of CB1954 drug substance to cGMP</gtr:description><gtr:id>4DC779B8-D0D0-47DA-8B90-BA27C502C520</gtr:id><gtr:impact>cGMP CB1954 drug substance provided for clinical trial</gtr:impact><gtr:outcomeId>GBRvABcirQL-1</gtr:outcomeId><gtr:partnerContribution>Developed method for purification of CB1954 by recrystallisation, to cGMP standard.</gtr:partnerContribution><gtr:piContribution>Engaged Aptuit for the work, and discussed approach and data with them.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Clinical Biomanufacturing Facilty</gtr:department><gtr:description>Adenoviral vector scale up production for clinical use</gtr:description><gtr:id>6B9DF9E6-07FE-4E83-B9FD-65BC8FAF3912</gtr:id><gtr:impact>Manufacture and fill have been completed. Quality and safety tests have now been completed, awaiting regulatory approvals for release to clinic</gtr:impact><gtr:outcomeId>7B6B40B56F5-1</gtr:outcomeId><gtr:partnerContribution>Production of viral stock for clinical trial use</gtr:partnerContribution><gtr:piContribution>Generation of novel viral vector for prostate cancer gene therapy</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Crucell</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Crucell Licence for PER.C6 cells</gtr:description><gtr:id>AA9AD6FB-27AC-42A3-A498-FD797B6AE9F8</gtr:id><gtr:impact>AdNRGM has been manufactured successfully, passing release test for absence of replication competent adenovirus</gtr:impact><gtr:outcomeId>eSabk9FHQyD-1</gtr:outcomeId><gtr:partnerContribution>Supplied PER.C6 cells onder licence and MTA to Clinical Biomanufacturing Facility, University of Oxford, for manufacture of AdNRGM virus; also provided relevant know-how and information for regulatory submission.</gtr:partnerContribution><gtr:piContribution>Identified requirement for PER.C6 cells to allow manufacture of AdNRGM virus free of replication-competent adenovirus contamination.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Interview</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6E67C1AF-B47F-4869-8E58-EAB348195CD8</gtr:id><gtr:impact>Interview for local television

Public knowledge of the project</gtr:impact><gtr:outcomeId>13C13AB9DA1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TV news coverage of first treated patient in AdUP trial</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7BBFF4AD-C150-48F8-8E92-264B9C8595DD</gtr:id><gtr:impact>With consent of the patient, the Midlands Today TV news team interviewed the first patient treated in the AdUP clinical trial, and showed scenes in theatre and subsequent in-patient recovery. The surgeons in theatre also spoke to camera about the trial.

Widely viewed across the Midlands, and also appeared on national BBC news website.</gtr:impact><gtr:outcomeId>mRPNHBzTS7c</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/uk-england-birmingham-24635924</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Poster, British Society for Gene Therapy 2010</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5C7E6E2B-8B8B-498D-AEBC-0EE6DC8BCEFC</gtr:id><gtr:impact>approx 400 delegates attended the symposium and thus had the opportunity to view the poster.

Discussions with delegates at the poster session</gtr:impact><gtr:outcomeId>k4Jb8XzXJD4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>352000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DOH Gene Therapy Vector Production to GMP Standards</gtr:description><gtr:end>2010-06-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>150E696A-1D37-41B0-86E7-7E09B572A521</gtr:id><gtr:outcomeId>63C2F66DA380</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Clinical Research Fellowship, 3 years, from core funding to the School of Cancer Sciences, University of Birmingham</gtr:description><gtr:end>2010-02-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>678689E4-05B3-44EF-922C-3C21325AA06C</gtr:id><gtr:outcomeId>323F0835BC90</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited onto MHRA Biologicals &amp;amp; Vaccines Expert Advisory Group</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>56A8F858-DF97-4565-A268-8BE2DC2A081F</gtr:id><gtr:impact>Advise MHRA on applications for market authorisation or clinical trials of biologicals and vaccines</gtr:impact><gtr:outcomeId>kWVLYNrcDPt</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>DEFRA-FERA horizon-scanning workshops on environmental risk of GMO medicines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E96192DA-CE6F-4186-8F1B-00ABAEEC46C3</gtr:id><gtr:outcomeId>C1Ak8qfEN4e</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of HSEs Scientific Advisory Committee on Genetic Modification</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BB1ED84F-669D-4A64-AEDE-F02AC5ADB965</gtr:id><gtr:impact>The committee advises the HSE on scientific issues relating to risk assessments and policy relating to GMOs. Contributed to development of the SACGM Compendium of Guidance, which provides guidance on risk assessment and compliance with the GMO regulations, in labs and also in the clinical arena.</gtr:impact><gtr:outcomeId>qrCMqzzSELu</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Training of clinical research fellows and PhD students in the area of gene therapy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3B522198-493E-4D66-A123-47FCA88A16CE</gtr:id><gtr:outcomeId>6A72D6A5D8F</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>CB1954 is the prodrug to be used in conjunction with the AdNRGM virus in a planned phase I clinical trial (AdUP). (It has already been used in previous clinical trials, e.g. with the related virus CTL102).
New batch of CB1954 was manufactured for the AdUP trial, shelf-life has recently been extended for a further 12 months in accordance with ongoing stability testing. Shelf life currently extended to October 2015. Funded from MRC award.</gtr:description><gtr:id>A762A43B-47CB-4D85-BC88-14F177D3229D</gtr:id><gtr:impact>Previous trials of CB1954 alone, or in conjunction with the CTL102 virus, established the safe dose that will be used in conjunction with the AdNRGM virus in the planned phase I trial. Two patients in the AdUP trial have now been treated with this material.</gtr:impact><gtr:outcomeId>csna3KVaBPR</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CB1954</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>CTC99020, CTC01010</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Replication deficient adenoviral vector expressing the E Coli Nitroreductase (NTR) and the GM-CSF genes.

GMP manufacture and fill completed. Quality and safety tests completed. Regulatory approval for Phase I trial received and first patient injected with 1x10^10 particles AdNRGM on 23Oct2013. As a result of ongoing stability testing, shel-life of AdNRGM has recently been extended for a further 12 months; shelf life currently extended to Sept 2015.</gtr:description><gtr:id>88069FE9-432C-483C-A39D-3E14342076CD</gtr:id><gtr:impact>Gene therapy vector for use in AdUP Phase I clinical trial in patients with hormone refractory, localised, prostate cancer. Two patients have been treated so far in the AdUP trial.</gtr:impact><gtr:outcomeId>EC52FC471AB</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>AdNRGM</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The first patient has been recruited to this clinical trial. He received intraprostatic injection of the AdNRGM adenovirus vector on 23rd October 2013, and intravenous infusion of the prodrug CB1954 on 25th October. Patient experienced potential DLT (elevated AST/ALT) during follow-up, subsequently resolved. This highlighted error if DLT definition in protocol, leading to a substantial amendment of the protocol.
Second patient was treated in February 2014, with no DLT or other significant issues.
By October 2014, it has become clear that the inclusion criteria are too narrow, there are too few eligible patients. Currently preparing substantial protocol amendment, removing the restriction to men with hormone-refractory prostate cancer. If accepted, men with locally recurrent prostate cancer post radiotherapy would be eligible, +/- prior hormonal therapy.</gtr:description><gtr:id>07B83D0B-DEC7-4BDB-879E-2B27091DDC0C</gtr:id><gtr:impact>This is the first use of AdNRGM in man, combining a prodrug activation therapy (using prodrug CB1954) with GM-CSF-mediated immune stimulation.</gtr:impact><gtr:outcomeId>aw893N5Cuom</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Initiation of AdUP phase I clinical trial</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:ukcrnIsctnId>ISRCTN06254734</gtr:ukcrnIsctnId><gtr:url>http://www.controlled-trials.com/ISRCTN06254734</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Detection and quantitation of immune responses of prostate cancer to gene therapy and other forms of treatment</gtr:description><gtr:id>A53EB98D-8544-4C8B-96D6-EFC852E6DACE</gtr:id><gtr:impact>Ability to measure immune responses occurring during gene therapy. Ability to measure immune responses occurring during other prostate cancer treatments (radiotherapy, hormone therapy etc). Correlations with treatment efficacy.</gtr:impact><gtr:outcomeId>9AFDE7A57C5</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cell based immuno assay to prostate specific tumour antigens (PSTA).</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Replication defective adenovirus expressing nitroreductase and human GM-CSF</gtr:description><gtr:id>3458405D-EB28-4C7D-BD87-EE2F230A5D7D</gtr:id><gtr:impact>This is the virus that will be used in the planned clinical trial in prostate cancer patients</gtr:impact><gtr:outcomeId>AvEwvCD4z6L</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>AdNRGM</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">G0502050</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>